ALK-Abelló

ALK-Abelló is a Denmark-based specialty pharmaceutical company that researches and manufactures allergy immunotherapy and related products for the prevention, diagnosis and treatment of allergic disease. Its approach targets the underlying cause of allergy rather than its symptoms, using natural allergens such as grass pollen and house dust mites. The company was founded in 1923 and is headquartered in Copenhagen.

The company's portfolio centres on allergy immunotherapy treatments, together with products covering respiratory allergies, food allergies, anaphylaxis and related conditions. Its technical work spans allergen extraction and standardisation, biological and bioprocess production, and quality control and analytical chemistry - an integrated sequence the company describes as "from farm to pharma", with analysis, standardisation and quality controls at each stage.

ALK-Abelló maintains production sites in four countries: Denmark, France, Spain and the United States, and operates offices in more than 20 countries. The company states a mission of helping five million people living with allergies by 2030, alongside continued growth and innovation. Its activities sit across the pharmaceuticals, healthcare, allergy and immunology, respiratory care and food allergy treatment sectors.